Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity
- PMID: 18505774
- DOI: 10.1177/1352458507088105
Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity
Abstract
Objectives: To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).
Method: 37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).
Results: Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).
Conclusion: The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.
Similar articles
-
Increased serum levels of soluble CD14 indicate stable multiple sclerosis.J Neuroimmunol. 2006 Dec;181(1-2):145-9. doi: 10.1016/j.jneuroim.2006.09.002. Epub 2006 Oct 13. J Neuroimmunol. 2006. PMID: 17046070
-
Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis.Acta Neurol Scand. 2009 Aug;120(2):119-22. doi: 10.1111/j.1600-0404.2008.01133.x. Epub 2008 Dec 2. Acta Neurol Scand. 2009. PMID: 19053950
-
Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.Mult Scler. 2009 Mar;15(3):316-22. doi: 10.1177/1352458508099482. Epub 2009 Jan 19. Mult Scler. 2009. PMID: 19153173
-
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.Rheumatology (Oxford). 2009 Oct;48(10):1190-6. doi: 10.1093/rheumatology/kep199. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589888 Review.
-
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.J Leukoc Biol. 2009 Sep;86(3):505-12. doi: 10.1189/jlb.0409230. Epub 2009 May 28. J Leukoc Biol. 2009. PMID: 19477910 Review.
Cited by
-
Microglia activation and anti-inflammatory regulation in Alzheimer's disease.Mol Neurobiol. 2010 Jun;41(2-3):115-28. doi: 10.1007/s12035-010-8106-8. Epub 2010 Mar 3. Mol Neurobiol. 2010. PMID: 20195797 Free PMC article. Review.
-
RAGE gene polymorphisms in patients with multiple sclerosis.J Mol Neurosci. 2009 Nov;39(3):360-5. doi: 10.1007/s12031-009-9291-7. J Mol Neurosci. 2009. PMID: 19757202
-
Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome.Sci Rep. 2016 Feb 23;6:21890. doi: 10.1038/srep21890. Sci Rep. 2016. PMID: 26902096 Free PMC article.
-
The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders.Nutrients. 2022 Jun 10;14(12):2421. doi: 10.3390/nu14122421. Nutrients. 2022. PMID: 35745150 Free PMC article. Review.
-
Is carbonyl/AGE/RAGE stress a hallmark of the brain aging?Pflugers Arch. 2021 May;473(5):723-734. doi: 10.1007/s00424-021-02529-y. Epub 2021 Mar 19. Pflugers Arch. 2021. PMID: 33742308 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
